Reuters logo
BRIEF-Corbus Pharmaceuticals presented data from phase 2 study of anabasum for treatment of systemic sclerosis
2017年6月15日 / 上午11点21分 / 3 个月前

BRIEF-Corbus Pharmaceuticals presented data from phase 2 study of anabasum for treatment of systemic sclerosis

June 15 (Reuters) - Corbus Pharmaceuticals Holdings Inc

* Corbus Pharmaceuticals presented data from phase 2 study of anabasum for the treatment of systemic sclerosis at the eular 2017 annual meeting

* Corbus Pharmaceuticals holdings - expects to complete enrollment of 52-week study of anabasum in 2018, expects to conclude study by end of 2019

* Corbus Pharmaceuticals holdings - also has ongoing 12-month, open-label extension to its phase 2 clinical study of anabasum for systemic sclerosis

* Corbus Pharmaceuticals holdings inc - plans to commence phase 3 study of anabasum for treatment of systemic sclerosis in q4 of 2017

* Expects to report data from the phase 2 clinical study of anabasum in q4 of 2017 Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below